Israel Biotech Fund I, L.P. 4
4 · Ayala Pharmaceuticals, Inc. · Filed May 14, 2020
Insider Transaction Report
Form 4
Israel Biotech Fund I, L.P.
10% Owner
Transactions
- Conversion
Common Stock
2020-05-12+369,231→ 2,878,362 total - Conversion
Common Stock
2020-05-12+211,757→ 3,090,119 total - Purchase
Common Stock
2020-05-12$15.00/sh+225,000$3,375,000→ 3,315,119 total - Conversion
Series A Preferred Stock
2020-05-12−738,462→ 0 total→ Common Stock (369,231 underlying) - Conversion
Series B Preferred Stock
2020-05-12−423,514→ 0 total→ Common Stock (211,757 underlying)
Footnotes (1)
- [F1]Each share of preferred stock was automatically converted into 0.5 shares of common stock upon the closing of the Issuer's initial public offering. The preferred stock had no expiration date.